

1 Melt electrowritten scaffolds with bone-inspired fibrous and mineral 2 architectures to enhance BMP2 delivery and human MSC osteogenesis

3 Kian F. Eichholz.^{1,2,3}, David A. Hoey.^{1,2,3,4}

4 ¹Dept. Mechanical, Aeronautical and Biomedical Engineering, Materials and Surface Science Institute, University of
5 Limerick, Limerick, Ireland

6 ²Trinity Centre for Bioengineering, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland

7 ³Dept. of Mechanical and Manufacturing Engineering, School of Engineering, Trinity College Dublin, Ireland

8 ⁴Advanced Materials and Bioengineering Research Centre, Trinity College Dublin & RCSI

9

10 1 Abstract

11 Material micro-architecture and chemistry play pivotal roles in driving cell behaviour. Bone at a
12 cellular level consists of arranged fibres with a cross-fibrillar mineral phase made up of curved nano-
13 sized needle shaped crystals. This nano-structured mineral architecture can bind and stabilise
14 proteins within bone for centuries and thus holds promise as a strategy for therapeutic delivery in
15 regenerative medicine. Herein, we use melt electrowriting (MEW) technology to create fibrous 3D
16 PCL micro-architectures. These scaffolds were further modified with an extrafibrillar coating of plate
17 shaped micron-sized calcium phosphate crystals (pHA), or with a novel extrafibrillar coating of
18 needle shaped nano-sized crystals (nnHA). A third scaffold was developed whereby nano-sized
19 crystals were placed intrafibrillarly during the MEW process (iHA). X-ray diffraction revealed altered
20 crystal structure and crystallinity between groups, with hydroxyapatite (HA) being the primary phase
21 in all modifications. Water contact angle was investigated revealing increased hydrophilicity with
22 extrafibrillar coatings, while tensile testing revealed enhanced stiffness in scaffolds fabricated with
23 intrafibrillar HA. Biological characterisation demonstrated significantly enhanced human
24 stem/stromal cell mineralisation with extrafibrillar coatings, with a 5-fold increase in mineral
25 deposition with plate like structures and a 14-fold increase with a needle topography, demonstrating
26 the importance of bone mimetic architectures. Given the protein stabilising properties of mineral,
27 these materials were further functionalised with BMP2. Extrafibrillar coatings of nano-needles
28 facilitated a controlled release of BMP2 from the scaffold which further enhanced mineral
29 deposition by osteoprogenitors. This study thus outlines a method for fabricating scaffolds with
30 precise fibrous micro-architectures and bone mimetic nano-needle HA extrafibrillar coatings which
31 significantly enhance mesenchymal stem/stromal cell (MSC) osteogenesis and therapeutic delivery
32 and thus hold great promise for bone tissue regeneration.

33 **2 Introduction**

34 Autografts are the gold standard for bone defect repair due to their osteoconductive, osteoinductive
35 and immunocompatible properties, but unfortunately are limited in supply [1]. Due to technology
36 advancements and an improved understanding of the physiological mechanisms of bone repair,
37 synthetic tissue engineering approaches have demonstrated great progress in developing
38 bioinspired materials that can promote bone formation [2]. These approaches continue to fall short
39 of the gold standard however, therefore, continued development is required. Bone is a complex,
40 hierarchical multi-phasic organ comprised primarily of mineralised collagen fibrils spanned by
41 additional continuous, cross-fibrillar mineral units [3, 4]. It was only recently identified that the first
42 fundamental component in this hierarchy is composed of needle-shaped mineral units of base 5 nm
43 and length 50 – 100 nm, which merge to form platelets and mineral stacks and aggregate to form
44 irregular 3D structures of size 200 – 300 nm which are crossfibrillar in nature [4]. It is the
45 combination of collagen and mineral with specific topographies, working in unison in this
46 hierarchical structure, which gives the bone both its excellent biological and mechanical properties.
47 Moreover, this mineral nano-topography identified in bone is believed to be a key contributor to
48 non-collagenous protein binding and stabilisation, preserving proteins for centuries within the tissue
49 without denaturation [5]. This therefore provides a potential strategy for therapeutic delivery in
50 regenerative medicine [6]. Recapitulating this unique multiscale architecture may represent an
51 innovative approach to develop effective bioinspired materials to promote bone repair.

52 Bone formation occurs following mesenchymal stem/stromal cell osteogenic differentiation into an
53 osteoblast, which begins laying down collagen fibrils and enriching the surrounding environment
54 with alkaline phosphatase and osteocalcin to promote mineral deposition within the collagen
55 template [7, 8]. The resulting nano-crystals are initially formed within collagen fibrils, eventually
56 nucleating to fill the voids forming a composite structure of mineral and collagen fibres
57 approximately 10 μm in diameter [9]. The underlying collagen fibrillar template is thus crucial in
58 dictating cellular behaviour in bone and many other tissues, with dysregulation of this unique
59 structure leading to undesirable outcomes including cell death, abnormal differentiation and tumour
60 development [10, 11]. Through the advent of new technology such as 3D printing, precise control of
61 scaffold architecture is now achievable [12]. Fused deposition modelling (FDM) can produce
62 scaffolds with defined fibre architecture creating pores of differing shapes [13] in addition to
63 facilitating mineral incorporation [14-18], which in turn drives mesenchymal stem/stromal cell (MSC)
64 differentiation down specific lineages. However, FDM is limited in that fibre diameters below 100
65 μm are difficult to fabricate. These relatively large fibres result in a pseudo-3D environment at the
66 scale of the cell [19]. Electrospinning is a common fabrication technique to produce physiological

67 fibre diameters on the nano/micron scale which have been utilised in bone tissue engineering
68 strategies [20, 21]. However, due to the unstable “whipping” motion of the electrospinning jet
69 during fibre deposition, there is limited control over fibre architecture using this approach. Melt
70 Electrospinning Writing (MEW) is a recently developed 3D printing technology which overcomes the
71 above limitations of FDM and electrospinning, being capable of fabricating and controlling the
72 deposition of micron-scale fibres [22-24]. This facilitates the manufacture of complex fibrous micro-
73 architectures [25-27] consistent with that seen in native extracellular matrix (ECM) including that of
74 bone. We recently utilised MEW to fabricate scaffolds with bone inspired fibre diameters of 10 μm
75 and investigated whether the fibre architecture in terms of degrees of alignment could influence
76 stem/stromal cell behaviour [28]. Interestingly, the combination of fibre diameter and alignment had
77 significant impact on cell shape, cell signalling and ultimately MSC osteogenesis, with a 90° fibre
78 architecture mediating a 4-fold increase in stem/stromal cell mineralization when compared to 10°
79 aligned architectures or a traditional random electrospun scaffold, demonstrating the critical role of
80 fibrillar architecture in mediating stem/stromal cell behaviour and highlighting MEW as a powerful
81 tool to fabricate physiological bioinspired environments for tissue engineering strategies.

82 In bone tissue, the mineral component makes up 60-70% of its dry weight, and is composed
83 primarily of non-stoichiometric apatite along with other loosely bound ions including Ca^{2+} , HPO_4^{2-} ,
84 CO_3^{2-} and Mg^{2+} in a hydrated layer at the surface [29]. As with fibrillar architecture, the mineral
85 structure in bone plays a key role in mediating cell behaviour, with deficiencies or changes in mineral
86 composition contributing to diseases such as osteoporosis [30]. This has been exploited in a host of
87 strategies for orthopaedic and dental applications, where materials and surfaces have been modified
88 with calcium phosphates with the aim of creating biomimetic materials which promote
89 osseointegration and tissue regeneration. This includes coatings for implant fixation, cements and
90 adhesives for orthopaedic and dental implants, and synthetic bone grafts [31]. A wide range of
91 commercially available materials have been investigated, including hydroxyapatite (HA), calcium
92 deficient apatite (CDA), α - and β tricalcium phosphate (TCP) and biphasic calcium phosphates such
93 as HA + TCP, with a range of other materials including dicalcium phosphate (DCP) and Tetracalcium
94 phosphate (TTCP) also being investigated [32]. As with fibrillar architecture, an ever increasing
95 appreciation for the importance of the architecture and particle size of the mineral phase is being
96 gained, which defines surface topography and thus has a considerable influence on cell behaviour
97 and scaffold performance [33]. When cultured on nano-scale HA (nHA) films with varying particles
98 sizes from 20 – 80 nm in diameter, MSCs exhibit a trend of greater viability and proliferation with
99 smaller particle sizes [34]. The osteogenic capacity of nHA has been further demonstrated in a range
100 of studies where cells have been cultured in nHA suspensions with particles of size between 20 – 100

101 nm, with cells demonstrating uptake of particles and exhibiting enhanced osteogenic differentiation
102 [35-37]. The role of HA particle size has also been investigated in the 3D printing of composite PCL-
103 HA blends, with enhanced proliferation and alkaline phosphatase (ALP) activity of MSCs seen with
104 nano-particles compared to micro-particles [38]. Remarkably, particle size has not only been shown
105 to be an important cue for MSC osteogenesis, but also plays a role in suppressing undesired cellular
106 outcomes in bone. This has been demonstrated via osteosarcoma inhibition [34] and reduced
107 melanoma proliferation [39] with nHA compared to larger particles, further reinforcing the
108 therapeutic potential of nano-scale particles for additional applications such as bone regeneration
109 following tumour ablation. A recent study has also demonstrated the regenerative capacity of grafts
110 with a needle surface topography *in-vivo*, with sub-micron needles triggering earlier and accelerated
111 bone formation [40].

112 Bone tissue also houses non-collagenous proteins and growth factors embedded within its
113 composite matrix, which are remarkably resolute and can be preserved for centuries due to the
114 great stability provided by the mineral structure [5]. It is thus of no surprise that the great binding
115 affinity to HA of a host of biological and synthetic components has been exploited for therapeutic
116 benefits. HA has been extensively used as a delivery mechanism for BMP2 protein with proven
117 success in a number of *in-vivo* models [41-43], while nHA particles have also been used for non-viral
118 gene delivery of BMP2 to enhance MSC osteogenesis [44, 45]. Anti-tumour drugs have also been
119 combined with nHA as a delivery vector, with potential applications in osteosarcoma chemotherapy
120 [46] and the development of targeted drug delivery methods [47]. Interestingly, protein binding and
121 stabilization is closely related to the nanoscale structural features of the mineral coatings [6],
122 demonstrating the importance of controlling this nHA architecture. In addition to the already pro-
123 osteogenic capabilities of biomimetic nHA, there is great potential to exploit its natural affinity to
124 further advance treatments by facilitating therapeutic delivery providing an extensive range of
125 enhanced regenerative benefits.

126 In this study, we aim to recapitulate the native structure of bone via the development of a
127 biomimetic tissue regeneration strategy comprised of a micro-fibrous matrix spanned by an
128 intrafibrillar nano-needle mineral phase stabilising bound protein for enhanced tissue regeneration.
129 Herein, we use melt electrowriting (MEW) technology to create fibrous 3D PCL micro-architectures.
130 These scaffolds were further modified with an extrafibrillar coating of plate shaped micron-sized
131 calcium phosphate crystals (pHA), or with a novel extrafibrillar coating of needle shaped nano-sized
132 crystals (nnHA). A third scaffold was developed whereby nano-sized crystals were placed
133 intrafibrillarly during the MEW process (iHA). Along with vastly differing surface topographies,

134 surface chemistry was also altered, with calcium/phosphate ratios within the range seen in healthy
135 native bone. Biological characterisation demonstrated significantly enhanced human stem/stromal
136 cell mineralisation with extrafibrillar coatings, with a needle topography producing the most robust
137 bone formation, demonstrating the importance of bone mimetic architectures. Given the protein
138 stabilising properties of mineral, these materials were further functionalised with BMP2.
139 Extrafibrillar coatings of nano-needles facilitated a controlled release of BMP2 from the scaffold
140 which further enhanced mineral deposition by osteoprogenitors. This study thus outlines a method
141 for fabricating scaffolds with precise fibrous micro-architectures and bone mimetic nano-needle HA
142 extrafibrillar coatings which significantly enhance MSC osteogenesis and therapeutic delivery and
143 thus holds great promise for bone tissue regeneration.

144 **3 Materials and methods**

145 **3.1 Scaffold fabrication**

146 *3.1.1 Polycaprolactone (PCL) melt electrowriting*

147 Fibrous scaffolds with a fibre diameter of 10 μm , square apparent pore size of 50 μm , and layer
148 offset of 300 μm were fabricated on a custom built MEW apparatus as previously described [28].
149 We have demonstrated that this fibrous scaffold architecture is optimal for MSC osteogenesis [28].
150 Briefly, heated air at a temperature of 90°C was circulated around a syringe to melt
151 polycaprolactone (PCL) (Sigma Aldrich 440744, average Mn 80,000), with air pressure being used to
152 extrude the polymer through a 21G needle with high voltage applied at a distance of 15 mm from a
153 grounded aluminium collector plate. Fibres were deposited with a 90° offset between subsequent
154 layers to result in a square pore shape. Scaffolds for control (C) groups were used without further
155 mineral modification.

156 *3.1.2 Plate hydroxyapatite (pHA) coating*

157 This coating was carried out via a saturated simulated body fluid (SBF) solution, as described by
158 Martine *et al* [48]. Reactions were carried out in 50ml conical tubes, with reagent volumes being
159 maintained at 40 ml at each step of the process and 6 scaffolds of dimension 3 x 3 cm being
160 processed per tube. Scaffolds were immersed in 70% ethanol for 15 min under vacuum and treated
161 with 2M NaOH for 45 min at 37°C following a 5 min vacuum treatment to remove air bubbles.
162 Scaffolds were rinsed 5 times in MilliQ water and immersed in 10x SBF, previously brought to a pH of
163 6 for 30 min at 37°C following a 5 min vacuum treatment. The coating step in 10x SBF was repeated
164 a further two times minus the vacuum treatment. Scaffolds were then treated with 0.5M NaOH for

165 30 min at 37°C, rinsed 5 times in MilliQ water and allowed to dry overnight. Scaffolds treated with
166 this coating method are defined as plate hydroxyapatite (pHA).

167 *3.1.3 Nano-needle hydroxyapatite (nnHA) coating*

168 We developed a nano-hydroxyapatite coating to coat scaffolds with nano-needle mineral units.
169 Sample pre- and post-processing was carried out as per the calcium phosphate coating procedure,
170 with the 10x SBF treatment step being substituted for alternative calcium and phosphate solutions
171 [49, 50]. The calcium solution was made with 0.05M calcium chloride dihydrate (Sigma Aldrich
172 C7902) in MilliQ water. The phosphate solution was made with 0.03M sodium phosphate tribasic
173 dodecahydrate (Sigma Aldrich S7778) and 0.01M sodium hydroxide in MilliQ water. The entire
174 coating procedure is outlined as below. Scaffolds were immersed in 70% ethanol for 15 min under
175 vacuum and treated with 2M NaOH for 45 min at 37°C following a 5 min vacuum treatment to
176 remove air bubbles. Scaffolds were rinsed 5 times in MilliQ water and added to 20 ml of the calcium
177 solution. 20 ml of the phosphate solution was slowly added to the calcium solution, and scaffolds
178 were incubated for 30 min at 37°C following a 5 min vacuum treatment. This coating procedure was
179 repeated a further two times minus the vacuum treatment. Scaffolds were then treated with 0.5M
180 NaOH for 30 min at 37°C, rinsed 5 times in MilliQ water and allowed to dry overnight. Scaffolds
181 treated with this coating method are defined as nano-needle hydroxyapatite (nnHA).

182 *3.1.4 Hydroxyapatite incorporated (iHA) PCL melt electrowriting*

183 A nHA-PCL blend was created by incorporating a 3.5wt% of nano-hydroxyapatite (Sigma Aldrich
184 677418) into the polymer. PCL and nano-hydroxyapatite with a total mass of 1 g was added to a
185 glass vial, with 10 ml of chloroform being added under stirring until dissolved. Particles were
186 dispersed in the solution by sonication for 1 h, after which it was poured into a glass dish and left
187 overnight for chloroform to evaporate. The resulting film was formed into pellets which were loaded
188 into 1 ml BD-Braun syringes. The syringes were heated for 1 h at 110°C, and centrifuged at 4,000g
189 for 60 s to remove air. The previous heating and centrifugation steps were repeated for a total of 8
190 cycles, or until a homogenous blend was present in the syringe with no air bubbles. MEW processing
191 parameters were optimised to facilitate controlled deposition of PCL-nHA blends, with temperature
192 increased to 110°C and voltage increased by approximately 0.5 kV. Scaffolds for this modification
193 method are defined as fibre incorporated hydroxyapatite (iHA).

194 **3.2 Scaffold characterisation**

195 *3.2.1 SEM imaging and Energy-dispersive X-ray spectroscopy*

196 For SEM imaging, samples were prepared for imaging by coating with gold/palladium for 40 s at a
197 current of 40 mA. For analysis with energy-dispersive X-ray spectroscopy (EDX), scaffolds were
198 carbon coated and analysed at a voltage of 15kV in a Zeiss ULTRA plus SEM with an 80mm² Oxford
199 Inca EDX detector. To investigate approximate calcium/phosphorus atomic ratios for each group,
200 spectra were acquired on scaffolds for 30 s (n=6, 2 technical replicates per scaffold). Element maps
201 were constructed by taking 2 frames at a resolution of 256 x 192 with map dwell of 4000 μ s and
202 linescan dwell of 2000 μ s.

203 *3.2.2 X-ray diffraction*

204 To obtain powder samples for x-ray diffraction (XRD) analysis, 10 x SBF was allowed to precipitate in
205 solution at a pH of 6, while for the nnHA group, calcium and phosphate solutions were mixed
206 together and allowed to precipitate. Solutions were centrifuged at 5,000g for 40 min to collect the
207 precipitate, which was then placed in dishes and dried for 4h at 50°C in an oven. The resulting
208 mineral was ground into a powder using a mortar and pestle. The hydroxyapatite powder used for
209 iHA was used for XRD analysis without any further processing. Samples were loaded in a Bruker D8
210 ADVANCE powder diffractometer and run for 1 h from 5 - 80° in the 2 θ range with a monochromatic
211 Cu-K α radiation source. Values for crystallinity and crystallite size were calculated using
212 DIFFRAC.SUITE EVA 4.1.1. Crystallite size was calculated from taking 5 measurements of the (211)
213 peak in pHA and iHA groups. In the iHA group, crystallite size was calculated from the peak in the
214 position of (211), (112) and (300), due to the broad peaks resulting in their merging.

215 *3.2.3 Calcium staining*

216 Samples were taken from scaffolds using a 2mm biopsy punch (n=5) and incubated with 1% alizarin
217 red s (Sigma Aldrich, A5533) in distilled water for 10 min at a pH of between 4.1 – 4.3. Samples were
218 rinsed 3 times with water and allowed to dry prior to imaging. To quantify bound stain, 400 μ l of
219 10% acetic acid was applied and samples incubated at room temperature for 30 min while shaking at
220 150rpm. The acetic acid was added to 1.5 ml tubes, vortexed vigorously and heated to 85°C for 10
221 min. Tubes were transferred to ice for 5 min, centrifuged at 20,000g for 15 min, and 300 μ l of the
222 supernatant was added to new tubes along with 120 μ l of 10% ammonium hydroxide. Standards
223 were made with dilutions of alizarin red solution in distilled water, with the pH of each adjusted to
224 between 4.1 – 4.3. Samples and standards were read at 405 nm in a 96-well plate.

225 3.2.4 Water contact angle

226 The water contact angle of all scaffold groups was quantified using a FTA125 contact angle analyzer
227 (First Ten Angstroms Inc.). Samples were prepared using an 8mm biopsy punch (n=6-7). All
228 measurements were taken 10 frames after contact of the water with the sample.

229 3.2.5 Tensile testing

230 Rectangular samples (n=4) of dimension 5 x 20 mm were taken from scaffolds and used for tensile
231 testing in a Zwick Z005 with 5N load cell (A.S.T. – Angewandte System Technik GmbH). Samples
232 were pre-loaded to 0.002N at a speed of 1mm/min, and then loaded at a speed of 10mm/min
233 with a time save interval of 0.1s. Load-displacement curves were graphed and used to determine
234 the stiffness, toe region stiffness and yield force for each group.

235 3.3 Human bone marrow mesenchymal stem/stromal (hMSC) cell culture

236 Scaffolds were punched to a diameter of 8 mm and UV sterilised for 20 min on each side before
237 being mounted in stainless steel holders and placed in 24-well plates. Scaffolds were then pre-wet in
238 a graded ethanol series of 100%, 90% and 70% for 20 min each before being washed three times in
239 phosphate buffered saline (PBS). They were then incubated overnight in DMEM with 10% FBS at
240 37°C. Human bone marrow mesenchymal stem/stromal cells (hMSCs) were isolated from bone
241 marrow (Lonza, US), trilineage potential verified (data not shown), and seeded at a number of
242 10,000 cells per scaffold. Scaffolds were transferred to new well plates after 24 h, and cultured in
243 osteogenic medium (OM) from day 3, which consisted of 10% FBS DMEM supplemented with
244 100nM dexamethasone, 10mM β -glycerol phosphate and 50 μ g/ml ascorbic acid. Medium was
245 changed every 3.5 days.

246 3.4 Proliferation

247 At days 1,7,14 and 21, scaffolds were added to 100 μ l lysis buffer (n=4) containing 0.2% Triton X-
248 100, 1mM Tris pH8, with phenylmethylsulfonyl fluoride (PMSF) being added at a ratio of 1:200 just
249 before use, and stored at -80°C. Before DNA quantification, samples underwent sonication for 60 s
250 and subjected to three freeze-thaw cycles in liquid nitrogen before being stored on ice. DNA content
251 was quantified using a Quant-iT™ PicoGreen™ dsDNA Assay Kit (Invitrogen, P7589), with excitation
252 and emission wavelengths of 485nm and 528nm respectively. The DNA content in 10,000 hSSCs
253 seeded and pelleted in centrifuge tubes was also quantified to calculate the total number of cells
254 present on scaffolds.

255 **3.5 Characterisation of hMSC osteogenic differentiation**

256 *3.5.1 Intracellular alkaline phosphatase (ALP)*

257 Intracellular ALP was quantified at days 14 and 21 (n=4). 50 µl of 5mM pNPP was added to wells
258 along with 10 µl of cell lysate and 70µl MilliQ water in a 96-well plate. Standards were comprised of
259 serial dilutions of p-Nitrophenyl phosphate (pNPP, Sigma Aldrich, N1891) with 10µl of 43µM ALP
260 enzyme (Sigma Aldrich, P6774) being added to each. Plates were incubated for 1 h in the dark at
261 room temperature, and reactions were then stopped using 20µl of 3M NaOH. Absorbance was read
262 on plates at 405 nm, and ALP activity was calculated as the amount of pNPP generated as a function
263 of sample volume and reaction time.

264 *3.5.2 Collagen production*

265 Scaffolds were cultured up to 21 days before evaluating collagen content. Cell-scaffold constructs
266 were rinsed in PBS, fixed in 10% neutral buffered formalin for 15 min and rinsed again in PBS before
267 storage at -20°C. Scaffolds were stained with 200µl of 1mg/ml of Direct Red 80 (Sigma Aldrich,
268 365548) in a saturated aqueous picric acid solution for 1 h with shaking at 150 rpm. Scaffolds were
269 then washed twice with 0.5% acetic acid and allowed to dry overnight before imaging. To quantify
270 collagen content, 500µl 0.5M NaOH was added to wells under shaking until stain was dissolved, and
271 solutions were added to 1.5 ml tubes. Tubes were centrifuged at 14,000g for 10 min to pellet debris.
272 Standards were made by adding direct red staining solution to 8µl of collagen I (Corning, #354249)
273 before centrifuging at 14,000g for 10 min and re-suspending the collagen in 500µl 0.5M NaOH. The
274 absorbance of samples and standards were read at 490 nm in 96-well plates.

275 *3.5.3 Calcium production*

276 Cell-scaffold constructs were investigated for total calcium content after 21 days using 1% alizarin
277 red S solution as previously described for calcium staining in scaffold characterisation. Cell-free
278 scaffolds were also cultured up to 21 days to determine the contribution of total calcium from cell
279 mineralisation versus the calcium present due to mineral modification of scaffolds.

280 **3.6 BMP2 functionalisation of MEW scaffolds**

281 *3.6.1 BMP2 adsorption onto scaffolds*

282 Scaffolds were prepared, sterilised and pre-wet in a graded ethanol series as previously described in
283 section 3.3 before being washed three times in PBS. Recombinant human BMP2 (Peprotech 120-02)
284 was diluted to 50 µg/ml in PBS, with 20 µl of solution containing a total of 1 µg BMP2 being placed

285 on each scaffold and incubated for 4 h at room temperature. BMP2 was then removed and scaffolds
286 were allowed to dry overnight.

287 3.6.2 *BMP2 release kinetics*

288 Scaffolds were placed in 48-well plates (n=4) and 200 μ l of PBS added to each. At each time-point,
289 PBS was removed and 1% BSA added to result in a final BSA concentration of 0.1%. 200 μ l of fresh
290 PBS was then added to each well. Samples were stored at -80°C until BMP2 quantity was determined
291 via ELISA (R&D Systems DY355-05). Cumulative BMP2 release was studied at time-points 1 h, 6 h,
292 and days 1, 3, 7, 14 and 21.

293 3.6.3 *Characterisation of osteogenic differentiation*

294 After BMP2 adsorption, 10,000 hMSCs were seeded onto scaffolds (n=4), and cultured up to 21 days
295 after which DNA content was investigated to determine total cell number. Scaffolds were also
296 cultured up to 21 days to assess osteogenic potential in terms of ALP activity, collagen production
297 and calcium production as described previously.

298 3.7 **Statistical analysis**

299 Tensile testing and material characterisation data is presented in terms of average and standard
300 deviation. Subsequent biological data is presented in terms of average and standard error of the
301 mean. Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparison
302 post-test. Data from the BMP2 loading study was analysed using two-way ANOVA and Bonferroni's
303 multiple comparison test.


304 4 **Results**

305 4.1 **MEW fibre topography is significantly altered by bulk and surface modification**

306 The topography of 90° orientate fibrous MEW scaffolds was investigated following modification with
307 calcium phosphate based materials, where significant changes were identified with minimal
308 influence on macroscopic scaffold morphology. Control fibres have a diameter of 9.1 μ m (SD = 1.0),
309 with relatively featureless surface topography (Figure 1A). The pHA coating protocol yields a rosette-
310 like arrangement of plates of average diameter 555.3 nm (SD = 193.2) and thickness 26.0 nm (SD =
311 8.6) (Figure 1B). Total fibre diameter including the coating is 13.5 μ m (SD = 2.6), giving an average
312 coating thickness in the pHA group of 2.2 μ m. In stark contrast to this, the nnHA coating protocol
313 results in the formation of nano-needles on the fibre surface (Figure 1C), with a length and diameter
314 of 100.0 nm (SD = 29.0) and 37.0 nm (SD = 7.1) respectively. These needles form occasional
315 aggregates which range in diameter from 150 – 500 nm. Total fibre diameter shows a minimal

316 increase compared to the control with a value of to 10.2 μm (SD = 1.0), yielding a total coating
317 thickness in this group of 0.55 μm . The incorporation of HA within fibres in iHA during the MEW
318 process yields minimal changes in surface topography, with the majority of visible particles being
319 seen as bulges just below the fibre surface, while several can also be seen to protrude above the
320 surface with no covering of PCL (Figure 1D). Particles have an average diameter of 147.2 nm (SD =
321 78.5), as measured within PCL fibres. The incorporation of HA also has an influence on the quality of
322 the MEW process, with periodic pulsing of the Taylor cone resulting in a larger fibre diameter
323 distribution (fibre diameter = 11.8 μm , SD = 4.2).

324



325


326 **Figure 1** SEM imaging of scaffold groups illustrating the “plate” coating morphology in pHA, “needle” morphology in nnHA,
327 and the presence of HA nanoparticles both within and protruding above the surface of the fibres in iHA.

328 4.2 CaP treatments modify surface chemistry

329 4.2.1 Element analysis

330 The coating chemistry and distribution in fibres was investigated via EDX analysis. The presence and
331 distribution of calcium and phosphorous was first investigated via element mapping where, as
332 expected, there was no detection in the control (Figure 2A). A consistent distribution of both
333 elements was seen in pHA and nnHA coated fibres, while a sparse distribution in the iHA group
334 confirmed the presence of HA particles within fibres. Carbon and oxygen were present in all groups
335 from the PCL, as well as calcium and phosphorous as seen in the spectra of all groups except the

336 control (Figure 2C, merge Figure 2D). A key difference in the pHA group was seen with the presence
 337 of sodium and magnesium in this coating. Ca/P ratios were investigated (Figure 2D) and were found
 338 to be close to stoichiometric hydroxyapatite with a ratio of 1.66 for the pHA group. The iHA group
 339 was investigated using both MEW scaffolds with HA incorporated, as well as the stock powder, with
 340 both having a resulting ratio of 1.76. The nnHA coating group deviated slightly from these findings,
 341 with a more calcium-rich HA with a ratio of 1.97 being identified.



342

343 **Figure 2** Chemical and physical characterisation of MEW-hydroxyapatite scaffolds. Element mapping of SEM images via EDX
 344 analysis illustrating the distribution of calcium and phosphorus in each group (A). Representative EDX spectra of all groups
 345 (B) and merge of spectra (C). Calcium to phosphorus ratios of EDX spectra (n=6 scaffolds, n=2 technical replicates) (D). XRD
 346 analysis of powder representative of CP, nnHA and iHA groups (E). Alizarin red staining of scaffolds (n=5) (F). Water contact
 347 angle illustrating increased hydrophilicity after hydroxyapatite coating (n=6-7) (G).

348 *4.2.2 Crystal structure of surface and bulk modifications*

349 XRD analysis was further conducted to characterise the crystal structure between groups (Figure 2E).
350 Brushite, hydroxylapatite and halite were identified in the pHA group, in close agreement with
351 previous literature [51], with a crystallinity of 61.3%. The nnHA and iHA groups were both shown to
352 be composed solely of hydroxyapatite, with crystallinity of 52.5% and 69.3% respectively. The
353 broader peaks in the nnHA group are indicative of a smaller crystallite size, which was found to be
354 8.5 nm. This is in comparison to the larger crystallite sizes in pHA and iHA, which were measured at
355 105.8 nm and 75.0 nm respectively.

356 *4.2.3 Calcium content of PCL modifications*

357 The total calcium content as determined via quantification of alizarin red staining was investigated
358 following scaffold modification with calcium phosphate minerals (Figure 2F). The calcium detected in
359 C is minimal, and is due to slight background staining of the PCL. The greatest amount of calcium was
360 found on pHA where nearly 150 μm was detected and was significantly greater than all other
361 approaches. nnHA contained the second largest quantities of calcium but was still 6-fold less than
362 that with pHA and was not significantly different to iHA. The calcium content detected in iHA is only
363 marginally greater than that detected from background staining (C) due to the majority of HA
364 particles being distributed throughout the bulk of the fibres.


365 *4.2.4 Surface treatment enhances material hydrophilicity*

366 The hydrophilicity of groups was investigated and found to correlate closely with their calcium
367 content (Figure 2G). This is seen in the complete spreading of water on pHA, which has the greatest
368 calcium content. The nnHA group also exhibited a significant degree of hydrophilicity, with a mean
369 contact angle of 56.0°. The C and iHA groups were both shown to be hydrophobic in comparison,
370 with contact angles of 117.3° and 117.1° respectively.

371 **4.3 Mechanical properties are enhanced via HA-incorporation into PCL MEW fibres**

372 Incorporation of HA into PCL in iHA is seen to increase its stiffness and yield force, while all coating
373 protocols have minimal influence on mechanical behaviour (Figure 3A,B). Stiffness in the linear
374 elastic region between 0.1 - 0.3 N is greatest in iHA scaffolds (Figure 3C), while stiffness in the toe
375 region is not seen to be significantly altered between groups (Figure 3D). Yield force of iHA scaffolds
376 is also significantly enhanced compared to all other groups, with an average fold increase of 1.4.

377



378


379 **Figure 3** Mechanical characterisation of scaffolds via tensile testing. The incorporation of HA into fibres (iHA) can be seen
 380 to alter the mechanical properties of PCL micro-fibres (A). Scaffolds before tensile testing, and after being loaded to
 381 approximately 50% of the yield strain (B). Significant increases in stiffness seen in iHA (C), with no change in toe region
 382 stiffness (D). Yield force of iHA scaffolds is also significantly increased (E). (n=4).

383 4.4 Attachment and proliferation of hMSCs

384 Cells adhere to scaffolds with an average seeding efficiency of 25%, with approximately 1,100 –
 385 3,400 cells remaining as quantified after 24 h post seeding. Adherent cells were found to branch
 386 across fibres resulting in elongated. Adherent hMSCs were commonly found branching across
 387 adjacent fibres as has been previously demonstrated with this fibre architecture [28]. Interestingly
 388 the pHA coating resulted in a slightly altered cellular morphology with hMSCs adhering and spreading
 389 across the deposited mineral, masking the underlying fibre architecture (Figure 4A). The initial cell
 390 seeding efficiency is lowest in the coated scaffold groups; pHA and nnHA. This trend is seen to level
 391 off by D7 however, where cell number reaches the initial seeding quantity at a number of 10,000 per
 392 scaffold. Cells then proliferate 2-fold per week for the remainder of the study, with an average of
 393 24,000 cells at D14 and 41,000 cells at D21. While there are no significant differences between

394 groups at any time-point, a trend of reduced cell number in the pHA scaffold group is seen at D14
395 and D21.

396




397

398 **Figure 4** SEM imaging of cell seeded scaffolds after 24 h culture (A) Cell proliferation as quantified by DNA content.
399 Proliferation in pHA scaffolds can be seen to be attenuated D14 compared to other scaffold groups (B). (n=4).

400 4.5 Surface treatment significantly enhances hMSC osteogenesis

401 4.5.1 ALP activity

402 No significant trends were identified in hMSC ALP expression between each scaffold at D14 and D21.
403 Total ALP activity can however be seen to be greater in nnHA and iHA groups at these time-points
404 (Figure 5A). Of note is the 2.2-fold increase in ALP activity in nnHA at D21 compared to D14, in
405 contrast with all other groups which remain constant between these time-points. Normalising these
406 results to cell number reveals no further trends in ALP expression (Figure 5B), which remains
407 relatively constant between groups.




408

409 **Figure 5** ALP activity in hMSCs at D14 and D21. No significant changes in total ALP activity (A) or ALP activity normalised to
410 cell number (B) were identified. (n=3-4).

411 4.5.2 hMSC Collagen production

412 Collagen production is shown to be enhanced in coated scaffold groups (Figure 6). Total collagen
413 quantity is greatest in pHA and nnHA at D21, with a 1.7 and 1.5-fold increase respectively compared
414 to control scaffolds. This effect is further magnified in the pHA group when normalising results to cell
415 number (Figure 6C), which is significantly greater than other groups. Collagen content per cell is 3.4-
416 fold greater in pHA than control, and over 2.5-fold greater than nnHA and iHA groups.

417




418

419 **Figure 6** Collagen production at D21 (A). Total collagen is enhanced in the pHA group compared to C (A), while a significant
420 increase compared to all groups is seen when collagen is normalised to cell number (B). (n=4). & = statistical significance
421 compared to all other groups (&&& = p<0.001).

422 4.5.3 hMSC Calcium production

423 As with previous outputs of osteogenic differentiation, mineral production is seen to be enhanced in
424 the coated scaffold groups (Figure 7A). These results encompass both mineralisation due to calcium
425 production by cells, as well as the calcium present due to the treatments prior to cell seeding. Total
426 mineral in pHA was 6.7-fold greater than C and iHA (Figure 7B). The greatest concentration following
427 21 days culture was found on scaffold nnHA, with this being over 12-fold greater than the calcium
428 content in C and iHA and 1.8-fold greater than pHA. These findings are further enhanced when
429 considering calcium due to cell mineralisation alone. The cell contribution to mineral in pHA was
430 59%, with the remainder the mineral from the scaffold coating. In stark contrast, 92% of the mineral
431 in nnHA is contributed by the cells. Considering this cell mineralisation alone, nnHA is over 14-fold
432 greater than C and 2.9-fold greater than pHA. When total calcium is normalised to cell number at
433 D21 (Figure 6C), calcium in pHA and nnHA groups are seen to be significantly greater than others,
434 with an over 10-fold increase in mineral production per cell in pHA and over 12-fold increase in nnHA
435 when compared to untreated control PCL scaffolds.




436

437 **Figure 7** Calcium content at D21 with contributions from scaffold and cell mineralisation (A). Total calcium content is
438 significantly enhanced in nnHA and pHA groups (B). Calcium content normalised to cell number is also enhanced in these
439 groups compared to C and iHA (C). (n=4). & = statistical significance compared to C and iHA groups (& = p<0.05, && =
440 p<0.01, &&& = p<0.001). * = p<0.05.

441 **4.6 Coating dissolution after long term culture**

442 After 21 days in culture, the pHA coating was found to be largely intact as seen via SEM imaging,
443 with minor changes seen in a more rough surface topography (Figure 8B) compared to at D1 (Figure
444 8A). In stark contrast to this, the nnHA coating is seen to have undergone considerable dissolution,
445 with loss of the nano-needle topography and formation of a coating of nano-spheres with diameter
446 of approximately 5-20 nm. Consistent fracturing of this coating can also be seen. The iHA group is
447 also considerably altered, with extensive precipitates seen at the fibre surface in contrast to the
448 relatively smooth fibre topography at D1.

449



450

451 **Figure 8** Fibre appearance after day 1 (A) and day 21 (B) in culture. Plates in the pHA group appear more rough at D21, with
452 morphology otherwise unchanged. The nnHA coating is significantly altered, with the initial nano-needles becoming
453 spherical and smaller in nature, and the coating exhibiting widespread fracturing. A greater amount of mineral
454 precipitation on the fibre surface is seen in iHA at D21, where the near-surface HA appears to act as sites for mineral
455 nucleation.

456


457 **4.7 Mineral architecture mediates BMP2 controlled release and further enhances hMSC** 458 **osteogenesis**

459 In order to investigate the capacity of mineral architectures to bind, stabilise, and release growth
460 factors, scaffolds were loaded with BMP2 and release kinetics and stem/stromal cell osteogenesis
461 investigated. There is an initial burst release of BMP2 from the C, pHA and iHA materials, with a
462 more sustained initial controlled release from nnHA (Figure 9A). The majority of the BMP2 is
463 released by C after 7 days with a total amount of approximately 50%, where the curve is seen to
464 plateau with minimal further release up to day 21, indicating a lower level of adsorption of the
465 protein with reduced affinity to the scaffold (Figure 9B). At 7 days, release percent from pHA and iHA

466 is 65% and 61% respectively, in contrast to nnHA, with a value of 46%. Between D7 and D21, nnHA
467 continues to maintain the greatest level of controlled release at a rate of 9.8% per week.

468 The controlled release of BMP2 from the MEW scaffolds is seen to enhance cell proliferation in each
469 group. Of particular note is the significant 1.9-fold increase in cell number on the nnHA scaffolds at
470 day 21 compared to control nnHA scaffolds, in addition to significantly enhanced DNA in BMP2
471 treated nnHA vs pHA, with a fold change of 2.9 (Figure 9C). The effect of BMP2 delivery on the
472 osteogenic differentiation of hMSCs was investigated via ALP activity, collagen and mineral
473 deposition as before. ALP increases were only seen in the C scaffolds, however as with all other
474 groups, this was not significant (Figure 9D). Collagen content was also investigated, with the greatest
475 increases in C and iHA compared to control scaffolds (Figure 9E). Overall collagen content was
476 between 16-20 μg in all groups, with greatest collagen content in nnHA after 21 days. Finally,
477 mineralisation is further enhanced in CP BMP2 functionalised scaffolds, with the greatest changes
478 seen in the nnHA and iHA groups, with increases of 259 μM and 372 μM respectively (Figure 9F). In
479 summary, the nnHA group exhibits the greatest potential for modification with additional factors, as
480 seen by the greatest level of sustained protein release, significantly enhanced DNA content, and the
481 greatest levels of collagen content and mineralisation content following 21 days in culture.

482



483

484 **Figure 9** Cumulative BMP2 release up to D3 (A) and up to D21(B) (n=4). Number of cells (C), ALP activity (D), collagen
 485 content (E) and calcium content (F) with BMP2 treatment at D21 compared to data from untreated scaffolds as presented
 486 in previous figures. * = statistical significance via one-way ANOVA and Tukey multiple comparison test within BMP2 group
 487 only. & = statistical significance vs C and iHA groups with same method as previously. # = statistical significance between
 488 Control and BMP2 in the nnHA group via two-way ANOVA and Bonferroni's multiple comparison test.

489 5 Discussion

490 Due to a lack of bone autograft supply, bioinspired synthetic alternative materials are required to
 491 enhance bone regeneration in critically sized defects. Cell behaviour and function are mediated by
 492 microenvironmental biophysical and biochemical cues, with the architecture and chemistry of the
 493 surrounding extracellular matrix being fundamental in this regard. Bone at a cellular level consists of
 494 arranged fibres with a cross-fibrillar mineral phase made up of curved nano-sized needle shaped

495 crystals. Recapitulating this unique multiscale architecture may represent an innovative approach to
496 develop effective bioinspired materials to promote bone regeneration. In this study, we utilise a 90°
497 fibrous MEW scaffold architecture, which we have previously optimised for human MSC
498 osteogenesis [28], and built on this foundation by developing biomimetic mineral functionalisation
499 strategies consisting of either intrafibrillar or cross fibrillar configurations. Interestingly using a novel
500 coating approach, we were able to grow nano-needle shaped HA (nnHA) crystals on the surface of
501 the MEW fibres which closely mimic that found in bone. These bioinspired nnHA topographies
502 significantly enhanced hMSC osteogenesis over traditional SBF plate HA (pHA) coatings or
503 intrafibrillar HA (iHA) scaffolds. Moreover, given the protein stabilising properties of mineral, we
504 demonstrated that nnHA facilitated a controlled release of BMP2 from the scaffold which further
505 enhanced mineral deposition by stem/stromal cells. This study thus outlines a method for fabricating
506 scaffolds with precise fibrous micro-architectures and bone mimetic nano-needle HA extrafibrillar
507 coatings which significantly enhance MSC osteogenesis and therapeutic delivery and thus hold great
508 promise for bone tissue regeneration.

509 The microarchitecture/topography, material chemistry, and mechanical properties of each MEW
510 scaffolds is altered followed CaP modifications. The concentrated SBF pHA coating technique
511 resulted in the formation of plates arranged in a “cauliflower” or “rosette” like coating morphology,
512 consistent with previously published findings using this approach [51-53] and typical of the plate or
513 “petal-like” morphology of apatite formed via supersaturated solutions [54]. In contrast, the nnHA
514 coating procedure which we have developed resulted in a vastly different morphology consisting of a
515 fine, extrafibrillar, nano-needle coating which form occasional aggregates, closely mimicking the
516 fundamental mineral units of bone in terms of morphology and composition recently identified [4].
517 The incorporation of HA into PCL in the iHA group does not have a significant influence on fibre
518 surface morphology, as seen by SEM and water contact angle measurements, however, mechanical
519 properties are enhanced with this approach. EDX analysis was further conducted to investigate the
520 elemental distribution and composition of modified fibres. The Ca/P ratios of all groups were within
521 the range seen in native bone, which has typical Ca/P ratios varying between 1.34 – 2.17 with a
522 median value of 1.69, as seen in samples from the femoral neck and the rib bones of healthy humans
523 [55-57] (note: weight ratios in references were converted to atomic ratios). To further investigate
524 the crystal structure of our scaffold groups, we performed an x-ray diffraction analysis. Interestingly,
525 the broad peaks of the XRD spectra of nnHA closely mimic those of native bone. This is in
526 comparison to the other groups which are more crystalline in nature. In summary, we have
527 demonstrated that our nnHA coating procedure closely mimics the nano-architecture, composition
528 and crystal structure of native bone.

529 Bone bioinspired architectures can significantly enhance MSC mediated bone formation, as we have
530 demonstrated via long term in-vitro studies. Cell behaviour was investigated on modified scaffolds
531 via proliferation and markers of osteogenic differentiation. Cell number was greatest in the nnHA
532 group after 21 days, with the lowest number of cells in the pHA group. This is consistent with
533 previous work demonstrating a trend of increased proliferation with reduced HA particle size [34].
534 We have also demonstrated a corresponding increase in ALP activity in nnHA, however, this result is
535 not significant. It is known that osteoprogenitor cells initially produce ALP and secrete collagen type
536 I, with further mineralisation occurring on this matrix at later time-points [58, 59]. We have shown
537 previously that the fibrous architecture of scaffolds can have a significant influence on hMSC
538 collagen production [28]. However, our current findings indicate that HA surface topography does
539 not augment collagen production. Further investigation of calcium deposition demonstrated highly
540 significant upregulation, particularly with nnHA coating. The majority of the contribution towards
541 total calcium content is seen to be due to cell-based mineralisation, indicating the significant
542 influence of nano-scale needles in this extrafibrillar coating in driving stem/stromal cell osteogenic
543 differentiation. There are several likely factors for this result, in addition to the influence of the
544 nano-particle size as discussed previously. Greater dissolution of this coating, as demonstrated by
545 SEM imaging after 21 days in culture will yield a greater release of calcium and phosphate ions into
546 the medium which can interact with cells and allow for reprecipitation, enhancing mineralisation
547 [60]. In addition, an inverse relationship between crystallinity and mineralisation has also been
548 shown [61], providing further evidence for the greater cell mineralisation on our nnHA group, which
549 has the lowest crystallinity. This therefore suggests that the superior bone formation demonstrated
550 with the nnHA coating is multifactorial, harnessing several mechanisms to maximise regeneration.

551 Nano-needle structured HA extrafibrillar coatings effectively bind, and slowly deliver stable BMP2,
552 enhancing hMSC proliferation and bone formation. We investigated the protein binding and release
553 capacity of these scaffold modifications via a BMP2 adsorption study. Recent studies have
554 demonstrated that mineral can stabilise bound proteins, preventing conformational changes,
555 maintaining biological activity for weeks during release and that this stabilisation is enhanced within
556 nanostructured coatings [6]. The nnHA group was shown to facilitate the most sustained release of
557 BMP2 over 21 days. Interestingly, this resulted in significantly enhanced proliferation in this group
558 demonstrating biological activity, while markers of osteogenic differentiation were also marginally
559 increased. A previous study has reported similar results, where continuous supplementation of
560 media with BMP2 resulted in enhanced proliferation of hMSCs without initiating osteogenic
561 differentiation [62]. However, many studies have also demonstrated the key role of BMP2 in
562 stimulating osteogenesis [63-65]. We believe that due to the high degree of mineralisation indicating

563 late stage differentiation, day 21 may be too late to capture elevated ALP expression, which is an
564 early differentiation marker. Consistent with previous findings in this paper, we also believe that
565 peak collagen levels for our scaffolds are being reached, as seen by the attenuated difference
566 between groups with BMP2 treatment compared to untreated scaffolds. While no significant
567 increases in calcium content were identified, it must be noted that the levels in nnHA are already 14-
568 fold greater than control scaffolds in the absence of BMP2 treatment, and the further increases in
569 mineral with BMP2 treatment in nnHA and iHA groups represent a change several fold-times greater
570 than basal calcium levels in untreated control scaffolds, which we have previously shown to
571 represent significantly enhanced mineralisation compared to random scaffolds [28]. In summary,
572 scaffolds with nnHA coating are shown to significantly enhance stem/stromal cell differentiation,
573 with the controlled release of BMP2 loaded scaffolds further contributing to this effect.

574 **6 Conclusions**

575 In conclusion, we utilised MEW technology to create fibrous 3D micro-architectures and further
576 modified these templates with a novel bioinspired extrafibrillar coating of needle shaped nano-sized
577 crystals (nnHA). This bone mimetic fibrous and mineral architecture significantly enhanced human
578 MSC osteogenesis over more established plate like mineral coatings. Moreover, extrafibrillar
579 coatings of nano-needles facilitated the binding, stabilisation, and controlled release of BMP2 from
580 the material which further enhanced MSC cell proliferation and bone formation. This study thus
581 outlines a method for fabricating scaffolds with precise fibrous micro-architectures and bone
582 mimetic nano-needle HA extrafibrillar coatings which significantly enhance MSC osteogenesis and
583 therapeutic delivery and thus hold great promise for bone tissue regeneration.

584 **7 Funding**

585 The authors would like to acknowledge funding from European Research Council (ERC) Starting
586 Grant (336882), Science Foundation Ireland (SFI) Support Grant SFI 13/ERC/L2864 and Irish Research
587 Council Postgraduate Scholarship (GOIPG/2014/493).

588 **8 References**

- 589 1. Yaszemski, M.J., et al., *Evolution of bone transplantation: molecular, cellular and tissue*
590 *strategies to engineer human bone*. *Biomaterials*, 1996. **17**(2): p. 175-85.

- 591 2. Winkler, T., et al., *A review of biomaterials in bone defect healing, remaining shortcomings*
592 *and future opportunities for bone tissue engineering: The unsolved challenge*. Bone Joint Res,
593 2018. **7**(3): p. 232-243.
- 594 3. Tzaphlidou, M., *Bone Architecture: Collagen Structure and Calcium/Phosphorus Maps*.
595 Journal of Biological Physics, 2008. **34**(1-2): p. 39-49.
- 596 4. Reznikov, N., et al., *Fractal-like hierarchical organization of bone begins at the nanoscale*.
597 Science, 2018. **360**(6388).
- 598 5. Asara, J.M., et al., *Protein sequences from mastodon and Tyrannosaurus rex revealed by*
599 *mass spectrometry*. Science, 2007. **316**(5822): p. 280-5.
- 600 6. Yu, X., et al., *Nanostructured Mineral Coatings Stabilize Proteins for Therapeutic Delivery*.
601 Adv Mater, 2017. **29**(33).
- 602 7. Alford, A.I., K.M. Kozloff, and K.D. Hankenson, *Extracellular matrix networks in bone*
603 *remodeling*. The International Journal of Biochemistry & Cell Biology, 2015. **65**: p. 20-31.
- 604 8. Rutkovskiy, A., K.-O. Stensløkken, and I.J. Vaage, *Osteoblast Differentiation at a Glance*.
605 Medical Science Monitor Basic Research, 2016. **22**: p. 95-106.
- 606 9. Kane, R. and P.X. Ma, *Mimicking the nanostructure of bone matrix to regenerate bone*.
607 Materials Today, 2013. **16**(11): p. 418-423.
- 608 10. Lu, P., et al., *Extracellular Matrix Degradation and Remodeling in Development and Disease*.
609 Cold Spring Harbor perspectives in biology, 2011. **3**(12): p. 10.1101/cshperspect.a005058
610 a005058.
- 611 11. Bonnans, C., J. Chou, and Z. Werb, *Remodelling the extracellular matrix in development and*
612 *disease*. Nature reviews. Molecular cell biology, 2014. **15**(12): p. 786-801.
- 613 12. Hutmacher, D.W., et al., *Mechanical properties and cell cultural response of*
614 *polycaprolactone scaffolds designed and fabricated via fused deposition modeling*. J Biomed
615 Mater Res, 2001. **55**(2): p. 203-16.
- 616 13. Di Luca, A., et al., *Tuning Cell Differentiation into a 3D Scaffold Presenting a Pore Shape*
617 *Gradient for Osteochondral Regeneration*. Advanced Healthcare Materials, 2016. **5**(14): p.
618 1753-1763.
- 619 14. Daly, A.C., et al., *3D Bioprinting for Cartilage and Osteochondral Tissue Engineering*.
620 Advanced Healthcare Materials, 2017. **6**(22): p. 1700298.
- 621 15. Cox, S.C., et al., *3D printing of porous hydroxyapatite scaffolds intended for use in bone*
622 *tissue engineering applications*. Materials Science and Engineering: C, 2015. **47**: p. 237-247.
- 623 16. Fierz, F.C., et al., *The morphology of anisotropic 3D-printed hydroxyapatite scaffolds*.
624 Biomaterials, 2008. **29**(28): p. 3799-3806.

- 625 17. Bergmann, C., et al., *3D printing of bone substitute implants using calcium phosphate and*
626 *bioactive glasses*. Journal of the European Ceramic Society, 2010. **30**(12): p. 2563-2567.
- 627 18. Inzana, J.A., et al., *3D printing of composite calcium phosphate and collagen scaffolds for*
628 *bone regeneration*. Biomaterials, 2014. **35**(13): p. 4026-4034.
- 629 19. Hogrebe, N.J., J.W. Reinhardt, and K.J. Gooch, *Biomaterial microarchitecture: a potent*
630 *regulator of individual cell behavior and multicellular organization*. Journal of Biomedical
631 Materials Research Part A, 2017. **105**(2): p. 640-661.
- 632 20. Labour, M.-N., et al., *Electrospun Poly-D-L-Lactic Acid Fibrous Scaffolds as a Delivery Vehicle*
633 *for Calcium Phosphate Salts to Promote In Situ Mineralisation and Bone Regeneration*.
634 Journal of Biomaterials and Tissue Engineering, 2018. **8**(2): p. 206-217.
- 635 21. Zhou, P., et al., *Loading BMP-2 on nanostructured hydroxyapatite microspheres for rapid*
636 *bone regeneration*. International Journal of Nanomedicine, 2018. **13**: p. 4083-4092.
- 637 22. Brown, T.D., P.D. Dalton, and D.W. Hutmacher, *Direct writing by way of melt electrospinning*.
638 Adv Mater, 2011. **23**(47): p. 5651-7.
- 639 23. Hochleitner, G., et al., *Additive manufacturing of scaffolds with sub-micron filaments via*
640 *melt electrospinning writing*. Biofabrication, 2015. **7**(3).
- 641 24. Wunner, F.M., et al., *Melt Electrospinning Writing of Three-dimensional Poly(epsilon-*
642 *caprolactone) Scaffolds with Controllable Morphologies for Tissue Engineering Applications*. J
643 Vis Exp, 2017(130).
- 644 25. de Ruijter, M., et al., *Out-of-Plane 3D-Printed Microfibers Improve the Shear Properties of*
645 *Hydrogel Composites*. Small, 2017: p. 1702773-n/a.
- 646 26. Castilho, M., et al., *Melt Electrowriting Allows Tailored Microstructural and Mechanical*
647 *Design of Scaffolds to Advance Functional Human Myocardial Tissue Formation*. Advanced
648 Functional Materials, 2018. **0**(0): p. 1803151.
- 649 27. Hochleitner, G., et al., *Melt electrowriting below the critical translation speed to fabricate*
650 *crimped elastomer scaffolds with non-linear extension behaviour mimicking that of*
651 *ligaments and tendons*. Acta Biomaterialia, 2018. **72**: p. 110-120.
- 652 28. Eichholz, K.F. and D.A. Hoey, *Mediating human stem cell behaviour via defined fibrous*
653 *architectures by melt electrospinning writing*. Acta Biomater, 2018. **75**: p. 140-151.
- 654 29. Rey, C., et al., *Bone mineral: update on chemical composition and structure*. Osteoporosis
655 international : a journal established as result of cooperation between the European
656 Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009.
657 **20**(6): p. 1013-1021.

- 658 30. Boskey, A.L., *Bone composition: relationship to bone fragility and antiosteoporotic drug*
659 *effects*. BoneKEy Reports, 2013. **2**: p. 447.
- 660 31. Habraken, W., et al., *Calcium phosphates in biomedical applications: materials for the*
661 *future?* Materials Today, 2016. **19**(2): p. 69-87.
- 662 32. Lc, C., *Next generation calcium phosphate-based biomaterials*. Dental materials journal,
663 2009. **28**(1): p. 1-10.
- 664 33. Zhou, H. and J. Lee, *Nanoscale hydroxyapatite particles for bone tissue engineering*. Acta
665 Biomaterialia, 2011. **7**(7): p. 2769-2781.
- 666 34. Cai, Y., et al., *Role of hydroxyapatite nanoparticle size in bone cell proliferation*. Journal of
667 Materials Chemistry, 2007. **17**(36): p. 3780-3787.
- 668 35. Yang, X., et al., *In Vitro Uptake of Hydroxyapatite Nanoparticles and Their Effect on*
669 *Osteogenic Differentiation of Human Mesenchymal Stem Cells*. Stem cells international,
670 2018. **2018**: p. 2036176-2036176.
- 671 36. Remya, N.S., et al., *An in vitro study on the interaction of hydroxyapatite nanoparticles and*
672 *bone marrow mesenchymal stem cells for assessing the toxicological behaviour*. Colloids and
673 Surfaces B: Biointerfaces, 2014. **117**: p. 389-397.
- 674 37. Liu, Y., et al., *In vitro effects of nanophase hydroxyapatite particles on proliferation and*
675 *osteogenic differentiation of bone marrow-derived mesenchymal stem cells*. Journal of
676 Biomedical Materials Research Part A, 2008. **90A**(4): p. 1083-1091.
- 677 38. Domingos, M., et al., *Three-dimensional printed bone scaffolds: The role of nano/micro-*
678 *hydroxyapatite particles on the adhesion and differentiation of human mesenchymal stem*
679 *cells*. Proc Inst Mech Eng H, 2016: p. 954411916680236.
- 680 39. Li, B., et al., *Preparation of nano-hydroxyapatite particles with different morphology and*
681 *their response to highly malignant melanoma cells in vitro*. Applied Surface Science, 2008.
682 **255**(2): p. 357-360.
- 683 40. Duan, R., et al., *Accelerated bone formation by biphasic calcium phosphate with a novel sub-*
684 *micron surface topography*. Eur Cell Mater, 2019. **37**: p. 60-73.
- 685 41. Xiong, L., et al., *BMP2-loaded hollow hydroxyapatite microspheres exhibit enhanced*
686 *osteinduction and osteogenicity in large bone defects*. International journal of
687 nanomedicine, 2015. **10**: p. 517-526.
- 688 42. Dellinger, J.G., J.A.C. Eurell, and R.D. Jamison, *Bone response to 3D periodic hydroxyapatite*
689 *scaffolds with and without tailored microporosity to deliver bone morphogenetic protein 2*.
690 Journal of Biomedical Materials Research Part A, 2005. **76A**(2): p. 366-376.

- 691 43. Notodihardjo, F.Z., et al., *Bone regeneration with BMP-2 and hydroxyapatite in critical-size*
692 *calvarial defects in rats*. Journal of Cranio-Maxillofacial Surgery, 2012. **40**(3): p. 287-291.
- 693 44. Gonzalez-Fernandez, T., et al., *Mesenchymal stem cell fate following non-viral gene*
694 *transfection strongly depends on the choice of delivery vector*. Acta Biomaterialia, 2017. **55**:
695 p. 226-238.
- 696 45. Curtin, C.M., et al., *Innovative Collagen Nano-Hydroxyapatite Scaffolds Offer a Highly*
697 *Efficient Non-Viral Gene Delivery Platform for Stem Cell-Mediated Bone Formation*. Advanced
698 Materials, 2012. **24**(6): p. 749-754.
- 699 46. Palazzo, B., et al., *Biomimetic Hydroxyapatite–Drug Nanocrystals as Potential Bone*
700 *Substitutes with Antitumor Drug Delivery Properties*. Advanced Functional Materials, 2007.
701 **17**(13): p. 2180-2188.
- 702 47. Sun, W., et al., *Biodegradable Drug-Loaded Hydroxyapatite Nanotherapeutic Agent for*
703 *Targeted Drug Release in Tumors*. ACS Applied Materials & Interfaces, 2018. **10**(9): p. 7832-
704 7840.
- 705 48. Martine, L.C., et al., *Engineering a humanized bone organ model in mice to study bone*
706 *metastases*. Nat. Protocols, 2017. **12**(4): p. 639-663.
- 707 49. Kumta, P.N., et al., *Nanostructured calcium phosphates for biomedical applications: novel*
708 *synthesis and characterization*. Acta Biomaterialia, 2005. **1**(1): p. 65-83.
- 709 50. Cunniffe, G.M., et al., *The synthesis and characterization of nanophase hydroxyapatite using*
710 *a novel dispersant-aided precipitation method*. J Biomed Mater Res A, 2010. **95**(4): p. 1142-9.
- 711 51. Vaquette, C., et al., *Effect of culture conditions and calcium phosphate coating on ectopic*
712 *bone formation*. Biomaterials, 2013. **34**(22): p. 5538-51.
- 713 52. Tas, A.C. and S.B. Bhaduri, *Rapid coating of Ti6Al4V at room temperature with a calcium*
714 *phosphate solution similar to 10× simulated body fluid*. Journal of Materials Research, 2011.
715 **19**(9): p. 2742-2749.
- 716 53. Kokubo, T., et al., *Solutions able to reproduce in vivo surface-structure changes in bioactive*
717 *glass-ceramic A-W3*. Journal of Biomedical Materials Research, 1990. **24**(6): p. 721-734.
- 718 54. Drouet, C., *Apatite Formation: Why It May Not Work as Planned, and How to Conclusively*
719 *Identify Apatite Compounds*. BioMed Research International, 2013. **2013**: p. 490946.
- 720 55. Zaichick, V. and M. Tzaphlidou, *Determination of calcium, phosphorus, and the*
721 *calcium/phosphorus ratio in cortical bone from the human femoral neck by neutron*
722 *activation analysis*. Appl Radiat Isot, 2002. **56**(6): p. 781-6.
- 723 56. Zaichick, V. and M. Tzaphlidou, *Calcium and phosphorus concentrations and the*
724 *calcium/phosphorus ratio in trabecular bone from the femoral neck of healthy humans as*

- 725 *determined by neutron activation analysis*. Applied Radiation and Isotopes, 2003. **58**(6): p.
726 623-627.
- 727 57. Tzaphlidou, M. and V. Zaichick, *Calcium, phosphorus, calcium-phosphorus ratio in rib bone of*
728 *healthy humans*. Biol Trace Elem Res, 2003. **93**(1-3): p. 63-74.
- 729 58. Huang, Z., et al., *The sequential expression profiles of growth factors from osteoprogenitors*
730 *[correction of osteroprogenitors] to osteoblasts in vitro*. Tissue Eng, 2007. **13**(9): p. 2311-20.
- 731 59. Birmingham, E., et al., *Osteogenic differentiation of mesenchymal stem cells is regulated by*
732 *osteocyte and osteoblast cells in a simplified bone niche*. Eur Cell Mater, 2012. **23**: p. 13-27.
- 733 60. Chang, Y.-L., C.M. Stanford, and J.C. Keller, *Calcium and phosphate supplementation*
734 *promotes bone cell mineralization: Implications for hydroxyapatite (HA)-enhanced bone*
735 *formation*. Journal of Biomedical Materials Research, 2000. **52**(2): p. 270-278.
- 736 61. Morgan, J., et al., *In vitro mineralization and implant calcium phosphate-hydroxyapatite*
737 *crystallinity*. Implant Dent, 1996. **5**(4): p. 264-71.
- 738 62. Lysdahl, H., et al., *Preconditioning Human Mesenchymal Stem Cells with a Low Concentration*
739 *of BMP2 Stimulates Proliferation and Osteogenic Differentiation In Vitro*. BioResearch Open
740 Access, 2014. **3**(6): p. 278-285.
- 741 63. Beederman, M., et al., *BMP signaling in mesenchymal stem cell differentiation and bone*
742 *formation*. Journal of biomedical science and engineering, 2013. **6**(8A): p. 32-52.
- 743 64. Huang, W., et al., *BMP-2 exerts differential effects on differentiation of rabbit bone marrow*
744 *stromal cells grown in two-dimensional and three-dimensional systems and is required for in*
745 *vitro bone formation in a PLGA scaffold*. Experimental Cell Research, 2004. **299**(2): p. 325-
746 334.
- 747 65. Li, C., et al., *Electrospun silk-BMP-2 scaffolds for bone tissue engineering*. Biomaterials, 2006.
748 **27**(16): p. 3115-3124.
- 749